Shots:
- Alvotech entered into a long-term agreement with Teva Pharmaceuticals to expand access to newly US FDA-approved higher concentration Adalimumab-ryvk, an interchangeable biosimilar to Humaira in US market
- The partnership agreement aims to broaden access and further availability assurance of biologics for patients at affordable prices in the US and globally
- Following commercialization collaboration between companies, SIMLANDI (Adalimumab-ryvk) will be commercialized by Teva in the US
Ref: Alvotech & Teva | Image: Alvotech & Teva | Press Release
Related News:- Samsung Bioepis Receives EC’s Marketing Authorization for Pyzchiva (Biosimilar, Stelara) to treat Autoimmune disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
